ROCKVILLE, Md., Aug. 30, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc.
(OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and
regeneration, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw
Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is
being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.
J.J. Finkelstein, CEO of RegeneRx, will provide an overview of the Company's business during
the live presentation and will be participating in one-on-one meetings with investors and analysts who are registered to attend
the conference.
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link
(www.rodmanevents.com) to register for the conference. Once your registration is confirmed, you will be
prompted to log into the conference website to request a one-on-one meeting with the Company.
Event: 19th Annual Rodman & Renshaw Global Investment Conference
Date: September 11, 2017
Time: 11:40 am Eastern Time
Location: Louis Salon; Lotte New York Palace Hotel in New York City
The presentation will be webcast live. To access the webcast, please visit www.rodmanevents.com. The webcast replay will remain available for 90
days following the live presentation.
About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com )
RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent
fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical
development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries
throughout the world.
RGN-259, the Company's Tβ4-based ophthalmic drug candidate, has been designated an orphan drug in the U.S. for the treatment
of neurotrophic keratopathy (NK). In July 2017, RegeneRx, through its U.S joint venture, ReGenTree
LLC, completed patient enrollment and treatment in its second Phase 3 clinical trial in approximately ~600 patients with dry eye
syndrome. Top line data is expected to be reported by the fourth quarter of 2017. The Company is simultaneously conducting
a 46-patient Phase 3 clinical trial in patients with NK targeted for completion in 2018. RGN-259 is also being developed in
patients with dry eye syndrome in Asia through RegeneRx's two Asian partnerships.
RGN-352, the Company's Tβ4-based injectable formulation, is a Phase 2-ready drug candidate designed to be administered
systemically to prevent and repair cardiac damage resulting from heart attacks and central nervous system tissue damage
associated disorders such as peripheral neuropathy, multiple sclerosis and traumatic brain injuries such as stroke.
RGN-137, also designated an orphan drug in the U.S., is the Company's Tβ4-based dermal gel formulation being developed for
epidermolysis bullosa, a rare skin condition. The Company's licensee, GtreeBNT, is sponsoring a Phase 3 clinical trial in the
U.S. and abroad and is expected to initiate the study in the third quarter of 2017.
For additional information about RegeneRx please visit www.regenerx.com.
Forward Looking Statements
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of
the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could
cause actual results to be materially different from historical results or from any future results expressed or implied by such
forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements
regarding our strategic and research partnerships, future royalty and milestone payments, regulatory applications and approvals,
the development of our drug candidates, the use of our drug candidates to treat various conditions, our growth strategy, and our
financial needs. All forward-looking statements are expectations and estimates based upon information obtained and calculated by
the Company at this time and are subject to change. Moreover, there is no guarantee any clinical trials will be successful or
confirm previous clinical results. Please view these and other risks described in the Company's filings with the Securities and
Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the
year ended December 31, 2016, and subsequent quarterly reports filed on Form 10-Q, as well as other
filings it makes with the SEC. Any forward-looking statements in this shareholder letter represent the Company's views only as of
the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company
specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required
by applicable law.
View original content:http://www.prnewswire.com/news-releases/regenerx-announces-participation-at-the-19th-annual-rodman--renshaw-global-investment-conference-in-new-york-september-10-12-2017-300511594.html
SOURCE RegeneRx Biopharmaceuticals, Inc.